anjianning

Anjianning is a biosimilar of adalimumab, a fully human monoclonal antibody that targets tumor necrosis factor alpha (TNF-α). By selectively binding to TNF-α, Anjianning prevents this pro-inflammatory cytokine from interacting with its receptors on cell surfaces, thereby reducing inflammation and tissue damage associated with autoimmune diseases. Developed in-house by BioRay Biopharmaceuticals and its subsidiary Hisun Biopharmaceutical Co., Ltd., Anjianning was first approved in China in 2019 and has since been approved for marketing in other countries such as Pakistan. It is indicated for the treatment of several inflammatory conditions including rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, ankylosing spondylitis, psoriasis (including pediatric plaque psoriasis), Crohn's disease (including pediatric Crohn's disease), and non-infectious uveitis[1][2][3].

Brand names

Anjianning

Other names

HS016HS-016HS 016